Head to Head Survey: Cidara Therapeutics (NASDAQ:CDTX) and Creative Medical Technology (NASDAQ:CELZ)

Cidara Therapeutics (NASDAQ:CDTX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility and Risk

Cidara Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cidara Therapeutics and Creative Medical Technology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cidara Therapeutics	$1.28 million	141.14	-$22.93 million	($30.09)	-0.55
Creative Medical Technology	$11,000.00	367.08	-$5.29 million	($3.71)	-0.62

Creative Medical Technology has lower revenue, but higher earnings than Cidara Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cidara Therapeutics and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cidara Therapeutics	-289.05%	-69.64%	-33.73%
Creative Medical Technology	N/A	-63.05%	-60.42%

Institutional & Insider Ownership

35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by company insiders. Comparatively, 2.8% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cidara Therapeutics and Creative Medical Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cidara Therapeutics	0	0	6	2	3.25
Creative Medical Technology	0	0	0	0	0.00

Cidara Therapeutics currently has a consensus price target of $39.14, indicating a potential upside of 138.24%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Cidara Therapeutics is more favorable than Creative Medical Technology.

Summary

Cidara Therapeutics beats Creative Medical Technology on 8 of the 15 factors compared between the two stocks.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.